As for drug sensitivity, the low-risk group was more sensitive to six inhibitors of the PI3K/AKT/mTOR pathway, such as rapamycin, which not only enhanced immunotherapeutic effects [18,22–25,29] but also blocked SASP-induced tumor progression (Fig. 7B). The gene discussed is AKT1; the disease is neoplasm.